The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Ileal Pouch
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
-
Corewell Health, Grand Rapids, Michigan, United States, 49503
Mayo Clinic Department of Gastroenterology, Rochester, Minnesota, United States, 55905
Washington University School of Medicine, Saint Louis, Missouri, United States, 63110
NYU Langone Health, New York, New York, United States, 10016
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599
Penn State Health (Milton S. Hershey Medical Center), Hershey, Pennsylvania, United States, 17033
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
Exegi Pharma, LLC,
Melody Khorrami, PharmD, RPh, STUDY_DIRECTOR, Exegi Pharma, LLC
2025-06